UNAIDS reports a 52% reduction in new HIV infections among children and a combined 33% reduction among adults and children since 2001 – UNAIDS shows dramatic acceleration towards reaching 2015 global targets on HIV. New HIV infections among adults and children were estimated at 2.3 million in 2012, a 33% reduction since 2001. New HIV infections among children have been reduced to 260 000 in 2012, a reduction of 52% since 2001.
Tamiflu Resistance Confirmed in H7N9 Flu Cases — Drug resistance in new China bird flu raises concern – Resistance easily develops when patients take antiviral drugs such as oseltamivir (tamiflu) for treating h7n9 influenza infections. Researcher’s analysis, which includes 14 patients who were hospitalized in Shanghai within 2 days of starting therapy with Tamiflu, appears in The Lancet.
Nanoparticles loaded with bee venom kill HIV
– Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at Washington University School of Medicine in St. Louis have shown. The finding is an important step toward developing a vaginal gel that may prevent the spread of HIV, the virus that causes AIDS.
Toddler ‘functionally cured’ of HIV infection, NIH-supported investigators report — Discovery provides clues for potentially eliminating HIV infection in other children – This is the first well-documented case of an HIV-infected child who appears to have been functionally cured of HIV infection. A two-year-old child born with HIV infection and treated with antiretroviral drugs beginning in the first days of life no longer has detectable levels of virus using conventional testing despite not taking HIV medication for 10 months.
Innovative policy to prevent mother-to-child transmission of HIV shows positive impact — New approach in Malawi dramatically increases the number of mothers on treatment – The number of pregnant and breastfeeding women in Malawi with HIV who started life-saving antiretroviral treatment increased by more than 700 percent in one year. The new treatment option, called Option B+, offers all pregnant or breastfeeding women infected with HIV lifelong antiretroviral treatment (ART), regardless of the stage of their HIV infection.
FDA approves first anti-diarrheal drug for HIV/AIDS patients — Fulyzaq is the second botanical drug approved by the agency – The U.S. Food and Drug Administration approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection.
More than half of young HIV-infected Americans are not aware of their status — Too many young people continue to become infected and few are tested for HIV – Young Americans between the ages of 13 and 24 represent more than a quarter of new HIV infections each year (26 percent) and most of these youth living with HIV (60 percent) are unaware they are infected. The most-affected young people are young gay and bisexual men and African-Americans.
FDA approves new combination pill for HIV treatment for some patients – Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection, is approved in US by FDA.
FDA approves first drug for reducing the risk of sexually acquired HIV infection — Evidence-based approach enhances existing prevention strategies – The U.S. Food and Drug Administration has approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners.
Natural HIV control may rely on sequence of T cell receptor protein — Protein on the surface of killer T cells appears to confer ability to suppress viral replication – The rare ability of some individuals to control HIV infection with their immune system alone appears to depend ? at least partially ? on specific qualities of the immune system’s killer T cells and not on how many of those cells are produced. Even among individuals sharing a protective version of an important immune system molecule ? the ability of HIV-specific killer T cells to control viral replication appears to depend on the particular sequence of the protein that recognizes HIV infected cells.
